Answers are grounded in this paper and cite their sources.
demonstrate the efficacy of a new technology, to document the burden associated to a given disease and either to support or to inform health policy, pricing and reimbursement decision making [8].In health economics, it is useful to perform cost-effectiveness and cost-utility studies by considering the preferences of patients [8,9]. The World Health Organization (WHO), for instance, undertakes cost-effectiveness and cost-utility assessments of interventions across national boundaries. In the UK, for example, the National Institute for Health and Clinical Excellence (NICE) determines which treatments and/or procedures should be used in the National Health Service (NHS) on the basis of their cost-effectiveness, and there are similar advisory or regulatory bodies in several other countries, including US, Canada, Australia and the Netherlands.To date, plenty of research is conducted in this field and relates, for example, to the choice of the instrument, methodological development, ability to capture specific health dimensions, and lots more. effectiveness of the same-day discharge (SDD) in comparison to that of regular care for primary total hip arthroplasty patients. This is achieved by analyzing the effect using the Oxford hip score (OHS), medical costs (both out-of-pocket and reimbursed), mean incremental costeffectiveness ratio (ICER), and quality-adjusted life years (QALYs) at 6-month follow up. By a standard cost-effectiveness analysis (CEA), this study would help physicians, government and health authorities to look at SDD in a more precise and efficient approach. Additionally, Shao et al. (2022) have also evaluated the cost-effectiveness of camrelizumab plus chemotherapy to treat sq-NSCLC from the Chinese healthcare system perspective. The findings of this economic evaluation approach would provide evidence for clinicians, government and health authorities in making optimal decisions in general clinical practice.To this end, our Research Topic was sealed with a methodological paper where Kharroubi and Kelleher (2022) have developed a novel Bayesian nonparametric model for estimating the utility values of health states defined by a generic descriptive system, to generate qualityadjusted life years and hence to conduct cost utility analysis of health care interventions. The new Bayesian statistical model also permits the utilization of evidence from one country as potential prior information for a study in another. The results of this study suggest that existing countries' valuations could be used as informative priors to generate better utility estimates than modeling the data from each country separately. This sort of analysis (borrowing strength from existing countries) could be particularly promising in terms of reducing the need for conducting large surveys in every country, which would in turn reduce the cost of cross-country valuation. This will be hugely important for countries where large-scale evaluation exercises are expensive and hard to conduct, particularly for countries with small population size or lowand middle-income countries.So as a final word, Health Related Quality Of Life in Health care has become the focus of health related research and practice especially after the COVID-19 crisis which have unveiled systems weaknesses and the need for future preparedness with more evidence based oriented actions and polices which this topic has aimed for.
No takes yet. Share an insight, caveat, or question.
Kharroubi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: